Table 4.

AChE-evoked synaptogenesis in cultured hippocampal neurones

Age of cells at start of AChE treatment	1 DIV		3 DIV		5 DIV		7 DIV
Treatment duration (days)	5	10	5	10	5	10	5	10
SV2a
Control	18 ± 5	28 ± 7	21 ± 4	31 ± 3	35 ± 5	29 ± 7	36 ± 6	42 ± 6
AChE	27 ± 5	42 ± 6	29 ± 6	48 ± 7	50 ± 6	44 ± 8	46 ± 5	49 ± 6
AChE: control ratio	1.5 ± 0.2	1.5 ± 0.3	1.4 ± 0.2	1.6 ± 0.3	1.4 ± 0.2	1.5 ± 0.3	1.3 ± 0.3	1.2 ± 0.9
PSD95
Control	6 ± 2	12 ± 4	18 ± 4	13 ± 4	26 ± 7	31 ± 3	34 ± 6	26 ± 5
AChE	5 ± 3	29 ± 3	28 ± 4	29 ± 6	37 ± 5	45 ± 7	48 ± 5	39 ± 3
AChE: control ratio	ND*	2.4 ± 0.9	1.6 ± 0.2	2.2 ± 0.2	1.4 ± 0.3	1.5 ± 0.4	1.4 ± 0.2	1.5 ± 0.4

Note. Postnatal hippocampal neurones at different ages in vitro (DIV) were treated with 0.01 U/ml AChE every day for 5 or 10 days. The number of puncta of the pre- and postsynaptic markers SV2a and PSD95 were counted in AChE-treated and control cells in five separate experiments. The data are expressed as immunoreactive puncta per 100 μm dendtrite (mean ± SD) and also as the ratio of puncta (treated/control). P < 0.05 for all comparisons.

^*ND, not determined because staining of PSD95 was predominantly diffuse.